EHT 1610 - 98%, high purity , CAS No.1425945-60-3

Item Number

E651619

• Specifications & Purity: ≥98%
• Biochemical and Physiological Mechanisms: EHT 1610 is a potent inhibitor of DYRK , with IC 50 s of 0.36 nM ( DYRK1A ), 0.59 nM ( DYRK1B ), respectively. EHT 1610 exhibits antileukemia effect, regulates cell cycle and induces cell apoptosis- .
• Storage Temp: Protected from light,Store at -20°C,Argon charged
• Shipped In: Ice chest + Ice pads

Product Description

EHT 1610 is a potent inhibitor of DYRK , with IC 50 s of 0.36 nM ( DYRK1A ), 0.59 nM ( DYRK1B ), respectively. EHT 1610 exhibits antileukemia effect, regulates cell cycle and induces cell apoptosis.

In Vitro

EHT 1610 induces apoptosis of primary ALL cells that were resistant to cytarabine. EHT 1610 dose-dependently induces apoptosis in B- and T-cell lines and primary human pediatric. EHT 1610 (; 72 h) inhibits DYRK1A, results loss of DYRK1A-mediated FOXO1 and STAT3 signaling, leading to preferential cell death in leukemic B cells. EHT 1610 (2.5-10 μM; 4-5 h) inhibits phosphorylation of FOXO1, STAT3 and cyclin D3, thus regulates late cell-cycle progression, mitochondrial ROS and DNA damage, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: MHH-CALL-4 cells Concentration: 0, 2.5, 5, 10 μM Incubation Time: 4, 5 hours Result: Reduced p-cyclin D3 (Thr283), and p-FOXO1 protein level in a dose-dependent manner.

In Vivo

EHT 1610 (20 mg/kg/d; i.p.; twice a day; 3 weeks) shows antileukemia activity against in leukemic aggressive model in mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Xenograft models of B-ALL in mice (12-14 weeks old)Dosage: 20 mg/kg Administration: Intraperitoneal injection; twice a day, 5 days on, 2 days off; 3 weeks Result: Reduced leukemic burden by approximately 8% and conferred a modest survival advantage.

Form:Solid

IC50& Target:IC50: 0.36 nM (DYRK1A), 0.59 nM (DYRK1B)